Stockscreener 앱 받기
6.98
66.59%
2.79
전일 마감가:
$4.19
열려 있는:
$6.98
하루 거래량:
9.57M
Relative Volume:
342.88
시가총액:
$13.45M
수익:
$6.50M
순이익/손실:
$-29.58M
주가수익비율:
-0.4273
EPS:
-16.3362
순현금흐름:
$-34.58M
1주 성능:
+74.50%
1개월 성능:
+91.23%
6개월 성능:
+46.33%
1년 성능:
+21.18%
1일 변동 폭
$5.99
$7.78
1주일 범위
$3.9467
$4.4801
52주 변동 폭
$3.10
$7.78
볼트 바이오테라퓨틱스 Stock (BOLT) Company Profile
명칭
Bolt Biotherapeutics Inc
전화
650-665-9295
주소
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
6.98 | 13.45M | 6.50M | -29.58M | -34.58M | -16.34 |
VRTX
Vertex Pharmaceuticals Inc
|
526.03 | 133.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.36 | 83.12B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
204.74 | 81.74B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
874.60 | 55.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.97 | 42.42B | 5.76B | 514.49M | 1.10B | 4.4813 |
볼트 바이오테라퓨틱스 Stock (BOLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-29 | 개시 | Rodman & Renshaw | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 개시 | Guggenheim | Buy |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
볼트 바이오테라퓨틱스 주식(BOLT)의 최신 뉴스
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock By Investing.com - Investing.com South Africa
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com India
Bolt Biotherapeutics CEO Quinn sells $58,402 in stock - Investing.com
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com India
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares By Investing.com - Investing.com Canada
Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares - Investing.com
Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares - Investing.com
Bolt Biotherapeutics (BOLT) CEO logs stock sales and an ESPP buy - Stock Titan
Bolt Biotherapeutics (BOLT) Climbs 6.43% to $3.56 as Shares Test Upper RangeMcClellan Oscillator - careplusvn.com
BOLT - Finviz
BOLT Q2 2026 Earnings: Wider-than-Expected Per-Share Loss of -$4.57 Highlights Cost PressuresEBITDA Margin Trends - vinanet.vn
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Barchart.com
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Return On Assets - vinanet.vn
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Earnings Deceleration Risk - careplusvn.com
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Balance Sheet Strength - dars.gov.et
Bolt Biotherapeutics (BOLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bolt (BOLT) Levels: Records a 2.60% Increase to $3.26 in the Current Update; Price Context: the Near-Term Reference Band Stretches From $3.10 to $3.42 in the Current UpdateTrend Following Picks - vinanet.vn
Bolt (BOLT) Quarterly Figures: The EPS Result Is Below Expectation; Price Reaction: Shares Fall 0.72%Buyback Announcement Report - vinanet.vn
Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - Vinanet
Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - vinanet.vn
Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BOLT Looks 49.0% Undervalued on GF Value™ Despite Clinical-Stage Challenges - GuruFocus
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - KHOU
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity - TradingView
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary - TradingView
BOLT: BDC-4182 trial progresses as cash runway extends into Q1 2027 amid lower Q2 expenses - TradingView
Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M - Stock Titan
Press Release: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - primepublishers.com
Bolt Biotherapeutics' Cancer Trial Data Expected With Q3 Results - Stock Titan
Bolt Biotherapeutics (BOLT) Advances 4.65% as Buyers Defend Key SupportHigh Volume Node - vinanet.vn
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BOLT Q2'26 Earnings: revenue estimate is 500.00K USD - TradingView
BOLT|Bolt Biotherapeutics Inc|Price:3.580|Chg%:-0.010 - TradingKey
Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Bolt Biotherapeutics Inc (BOLT) Cash Flow - TradingKey
TradingKey - TradingKey
BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110 - TradingKey
BOLT Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerAdjusted Earnings Analysis - careplusvn.com
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BOLT Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Season Review - dars.gov.et
Curis (CRIS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CRIS - MarketBeat
볼트 바이오테라퓨틱스 (BOLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
볼트 바이오테라퓨틱스 주식 (BOLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemec Sarah | Senior VP, Finance and PAO |
Sep 18 '26 |
Sale |
3.24 |
4,077 |
13,195 |
17,082 |
| Quinn William P. | President, CEO and CFO |
Sep 18 '26 |
Sale |
3.24 |
9,132 |
29,555 |
25,384 |
| Nemec Sarah | Senior VP, Finance and PAO |
Sep 17 '26 |
Sale |
3.32 |
2,922 |
9,696 |
21,159 |
| Quinn William P. | President, CEO and CFO |
Sep 17 '26 |
Sale |
3.32 |
6,545 |
21,718 |
34,516 |
| Yonehiro Grant | Chief Operating Officer |
Sep 17 '26 |
Sale |
3.32 |
4,909 |
16,290 |
24,119 |
| Nemec Sarah | Senior VP, Finance and PAO |
Sep 16 '26 |
Sale |
3.77 |
843 |
3,181 |
24,081 |
| Yonehiro Grant | Chief Operating Officer |
Sep 16 '26 |
Sale |
3.77 |
1,417 |
5,348 |
29,028 |
| Quinn William P. | President, CEO and CFO |
Sep 16 '26 |
Sale |
3.77 |
1,889 |
7,129 |
41,061 |
| Quinn William P. | President, CEO and CFO |
Jun 05 '26 |
Buy |
3.88 |
637 |
2,469 |
2,950 |
| Nemec Sarah | Senior VP, Finance and PAO |
Jun 05 '26 |
Buy |
3.88 |
509 |
1,973 |
1,924 |
6.79%
자본화:
|
볼륨(24시간):